- Home
- NTRA vs CBOE Comparison
NTRA vs CBOE Comparison
Compare NTRA & CBOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- CBOE
- Stock Information
- Founded
- NTRA 2003
- CBOE 1973
- Country
- NTRA United States
- CBOE United States
- Employees
- NTRA N/A
- CBOE N/A
- Industry
- NTRA Medical Specialities
- CBOE Investment Bankers/Brokers/Service
- Sector
- NTRA Health Care
- CBOE Finance
- Exchange
- NTRA Nasdaq
- CBOE Nasdaq
- Market Cap
- NTRA 24.9B
- CBOE 25.6B
- IPO Year
- NTRA 2015
- CBOE 2010
- Fundamental
- Price
- NTRA $173.19
- CBOE $243.71
- Analyst Decision
- NTRA Strong Buy
- CBOE Hold
- Analyst Count
- NTRA 17
- CBOE 13
- Target Price
- NTRA $192.41
- CBOE $234.15
- AVG Volume (30 Days)
- NTRA 1.1M
- CBOE 789.8K
- Earning Date
- NTRA 11-11-2025
- CBOE 10-31-2025
- Dividend Yield
- NTRA N/A
- CBOE 1.18%
- EPS Growth
- NTRA N/A
- CBOE 18.01
- EPS
- NTRA N/A
- CBOE 8.52
- Revenue
- NTRA $1,964,250,000.00
- CBOE $4,531,800,000.00
- Revenue This Year
- NTRA $24.28
- CBOE N/A
- Revenue Next Year
- NTRA $15.50
- CBOE $4.38
- P/E Ratio
- NTRA N/A
- CBOE $28.57
- Revenue Growth
- NTRA 44.38
- CBOE 18.98
- 52 Week Low
- NTRA $117.27
- CBOE $187.30
- 52 Week High
- NTRA $183.00
- CBOE $255.27
- Technical
- Relative Strength Index (RSI)
- NTRA 58.16
- CBOE 54.78
- Support Level
- NTRA $167.99
- CBOE $234.72
- Resistance Level
- NTRA $174.75
- CBOE $248.99
- Average True Range (ATR)
- NTRA 5.37
- CBOE 4.71
- MACD
- NTRA 0.16
- CBOE 0.43
- Stochastic Oscillator
- NTRA 91.00
- CBOE 63.00
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.